Atypical hemolytic-uremic syndrome: The interplay between complements and the coagulation system

Ali Nayer, Arif Asif

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Hemolytic-uremic syndrome (HUS) is a rare life-threatening disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and impaired renal function. A thrombotic microangiopathy underlies the clinical features of HUS. In the majority of cases, HUS follows an infection with toxin-producing bacteria such as verotoxin-producing Escherichia coli. In some cases, HUS is not preceded by a clinically apparent infection, and therefore, is named atypical HUS. The prognosis of atypical HUS is poor. While mortality approaches 25% during the acute phase, end-stage renal disease develops in nearly half of patients within a year. Evidence is accumulating that complement activation through the alternative pathway is at the heart of the pathophysiology leading to atypical HUS. Genetic abnormalities involving complement regulatory proteins and complement components form the molecular basis for complement activation. Since microvascular thrombosis is a quintessential feature of atypical HUS, complements and the coagulation system must work in tandem to give rise to the pathologic alterations observed in this condition. Here, a brief discussion of clinical and morphologic features of atypical HUS is followed by a concise presentation of the complement and coagulation systems. The interplay between complements and the coagulation system is graphically highlighted. Last but not least, conventional and emerging therapies for atypical HUS are outlined.

Original languageEnglish
Pages (from-to)340-345
Number of pages6
JournalIranian Journal of Kidney Diseases
Volume7
Issue number5
StatePublished - Oct 4 2013

Fingerprint

Hemolytic-Uremic Syndrome
Thrombotic Microangiopathies
Shiga-Toxigenic Escherichia coli
Alternative Complement Pathway
Complement Activation
Hemolytic Anemia
Infection
Thrombocytopenia
Chronic Kidney Failure
Atypical Hemolytic Uremic Syndrome
Complement System Proteins
Thrombosis
Bacteria
Kidney
Mortality
Therapeutics

Keywords

  • Atypical hemolytic-uremic syndrome
  • Blood coagulation disorders
  • Complement system proteins

ASJC Scopus subject areas

  • Nephrology

Cite this

Atypical hemolytic-uremic syndrome : The interplay between complements and the coagulation system. / Nayer, Ali; Asif, Arif.

In: Iranian Journal of Kidney Diseases, Vol. 7, No. 5, 04.10.2013, p. 340-345.

Research output: Contribution to journalArticle

@article{1203869ddc7f45a5ac82764665487bcf,
title = "Atypical hemolytic-uremic syndrome: The interplay between complements and the coagulation system",
abstract = "Hemolytic-uremic syndrome (HUS) is a rare life-threatening disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and impaired renal function. A thrombotic microangiopathy underlies the clinical features of HUS. In the majority of cases, HUS follows an infection with toxin-producing bacteria such as verotoxin-producing Escherichia coli. In some cases, HUS is not preceded by a clinically apparent infection, and therefore, is named atypical HUS. The prognosis of atypical HUS is poor. While mortality approaches 25{\%} during the acute phase, end-stage renal disease develops in nearly half of patients within a year. Evidence is accumulating that complement activation through the alternative pathway is at the heart of the pathophysiology leading to atypical HUS. Genetic abnormalities involving complement regulatory proteins and complement components form the molecular basis for complement activation. Since microvascular thrombosis is a quintessential feature of atypical HUS, complements and the coagulation system must work in tandem to give rise to the pathologic alterations observed in this condition. Here, a brief discussion of clinical and morphologic features of atypical HUS is followed by a concise presentation of the complement and coagulation systems. The interplay between complements and the coagulation system is graphically highlighted. Last but not least, conventional and emerging therapies for atypical HUS are outlined.",
keywords = "Atypical hemolytic-uremic syndrome, Blood coagulation disorders, Complement system proteins",
author = "Ali Nayer and Arif Asif",
year = "2013",
month = "10",
day = "4",
language = "English",
volume = "7",
pages = "340--345",
journal = "Iranian Journal of Kidney Diseases",
issn = "1735-8582",
publisher = "Iranian Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Atypical hemolytic-uremic syndrome

T2 - The interplay between complements and the coagulation system

AU - Nayer, Ali

AU - Asif, Arif

PY - 2013/10/4

Y1 - 2013/10/4

N2 - Hemolytic-uremic syndrome (HUS) is a rare life-threatening disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and impaired renal function. A thrombotic microangiopathy underlies the clinical features of HUS. In the majority of cases, HUS follows an infection with toxin-producing bacteria such as verotoxin-producing Escherichia coli. In some cases, HUS is not preceded by a clinically apparent infection, and therefore, is named atypical HUS. The prognosis of atypical HUS is poor. While mortality approaches 25% during the acute phase, end-stage renal disease develops in nearly half of patients within a year. Evidence is accumulating that complement activation through the alternative pathway is at the heart of the pathophysiology leading to atypical HUS. Genetic abnormalities involving complement regulatory proteins and complement components form the molecular basis for complement activation. Since microvascular thrombosis is a quintessential feature of atypical HUS, complements and the coagulation system must work in tandem to give rise to the pathologic alterations observed in this condition. Here, a brief discussion of clinical and morphologic features of atypical HUS is followed by a concise presentation of the complement and coagulation systems. The interplay between complements and the coagulation system is graphically highlighted. Last but not least, conventional and emerging therapies for atypical HUS are outlined.

AB - Hemolytic-uremic syndrome (HUS) is a rare life-threatening disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and impaired renal function. A thrombotic microangiopathy underlies the clinical features of HUS. In the majority of cases, HUS follows an infection with toxin-producing bacteria such as verotoxin-producing Escherichia coli. In some cases, HUS is not preceded by a clinically apparent infection, and therefore, is named atypical HUS. The prognosis of atypical HUS is poor. While mortality approaches 25% during the acute phase, end-stage renal disease develops in nearly half of patients within a year. Evidence is accumulating that complement activation through the alternative pathway is at the heart of the pathophysiology leading to atypical HUS. Genetic abnormalities involving complement regulatory proteins and complement components form the molecular basis for complement activation. Since microvascular thrombosis is a quintessential feature of atypical HUS, complements and the coagulation system must work in tandem to give rise to the pathologic alterations observed in this condition. Here, a brief discussion of clinical and morphologic features of atypical HUS is followed by a concise presentation of the complement and coagulation systems. The interplay between complements and the coagulation system is graphically highlighted. Last but not least, conventional and emerging therapies for atypical HUS are outlined.

KW - Atypical hemolytic-uremic syndrome

KW - Blood coagulation disorders

KW - Complement system proteins

UR - http://www.scopus.com/inward/record.url?scp=84884781209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884781209&partnerID=8YFLogxK

M3 - Article

C2 - 24072143

AN - SCOPUS:84884781209

VL - 7

SP - 340

EP - 345

JO - Iranian Journal of Kidney Diseases

JF - Iranian Journal of Kidney Diseases

SN - 1735-8582

IS - 5

ER -